Correction to "Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer".
APA
Xue L, Yu X, et al. (2025). Correction to "Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer".. Molecular pharmaceutics, 22(9), 5710-5711. https://doi.org/10.1021/acs.molpharmaceut.5c01102
MLA
Xue L, et al.. "Correction to "Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer".." Molecular pharmaceutics, vol. 22, no. 9, 2025, pp. 5710-5711.
PMID
40802348
같은 제1저자의 인용 많은 논문 (5)
- Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial.
- The efficacy and toxicity of TRT on metastatic NSCLC in patients treated with targeted therapy and chemoimmunotherapy.
- Efficacy and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer With Lymph Node Metastasis.
- Tumor microenvironment and immunometabolic reprogramming in pancreatic ductal adenocarcinoma: Barriers and breakthroughs in immunotherapy.
- Autophagy regulates anti-angiogenic property of lenvatinib in thyroid cancer.